The bidding war over biotechnology company Metsera (MTSR) has intensified, drawing fierce competition from pharmaceutical ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

But Pfizer (PFE) isn't going down without a fight. While Novo Nordisk's (NVO) bid could top Pfizer's by up to $2.7 billion, Pfizer Chief Executive Albert Bourla called it "illusory" and said it can't ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as ...

Pfizer beat earnings expectations decisively this morning, with shares of PFE gapping up more than 12% in pre-market trading.

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported third-quarter profit of $3.54 billion. On a per-share basis, the New York-based company said it had net income of 62 cents.

The ‘Big Short’ investor Michael Burry disclosed a new regulatory 13F filing on November 3, revealing several portfolio ...